✉news ScienceScience first seen 12 h ago, last 11 h ago, peak #19
Qurient's CDK7 Inhibitor Q901 Shows Synergy with ADCs in Science Advances
Original: Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs
South Korean biotech Qurient announced that its research has been published in Science Advances, showing that its selective CDK7 inhibitor Q901 works synergistically with TOP1 inhibitor-based antibody-drug conjugates. The finding supports combining Q901 with established cancer treatments and may strengthen the company's position in oncology drug development, drawing attention from investors and the biomedical research community.
Why now: A peer-reviewed publication in a prestigious journal validates the company's drug combination strategy, which matters to oncology researchers and biotech investors.
Rank over time, top of the chart is #1. 2 snapshots from 12 h ago to 11 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/564369